

Thomas Täting

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1027105/publications.pdf>

Version: 2024-02-01

184
papers

12,601
citations

22153

59
h-index

27406

106
g-index

199
all docs

199
docs citations

199
times ranked

19882
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor cell intrinsic Toll-like receptor 4 signaling promotes melanoma progression and metastatic dissemination. <i>International Journal of Cancer</i> , 2022, 150, 142-151.	5.1	7
2	CRISPRitope: A generic platform to model target antigens for adoptive T cell transfer therapy in mouse tumor models. <i>STAR Protocols</i> , 2022, 3, 101038.	1.2	1
3	XIAP promotes melanoma growth by inducing tumour neutrophil infiltration. <i>EMBO Reports</i> , 2022, 23, e53608.	4.5	12
4	Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, 3741-3749.	1.6	33
5	Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group. <i>European Journal of Cancer</i> , 2021, 143, 43-45.	2.8	1
6	Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1763-1771.	2.5	2
7	The myeloid cell type I IFN system promotes antitumor immunity over pro-tumoral inflammation in cancer T cell therapy. <i>Clinical and Translational Immunology</i> , 2021, 10, e1276.	3.8	5
8	E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion. <i>Oncogene</i> , 2021, 40, 5567-5578.	5.9	3
9	Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. <i>Immunity</i> , 2020, 53, 564-580.e9.	14.3	27
10	The aryl hydrocarbon receptor promotes inflammation-induced dedifferentiation and systemic metastatic spread of melanoma cells. <i>International Journal of Cancer</i> , 2020, 147, 2902-2913.	5.1	20
11	Successful treatment of non-uremic calciphylaxis with bisphosphonate. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1498-1500.	0.8	2
12	Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. <i>Journal of Clinical Oncology</i> , 2020, 38, 2543-2551.	1.6	40
13	Cannabinoid Receptor 2 Modulates Maturation of Dendritic Cells and Their Capacity to Induce Hapten-Induced Contact Hypersensitivity. <i>International Journal of Molecular Sciences</i> , 2020, 21, 475.	4.1	8
14	Activated Hgf-Met Signaling Cooperates with Oncogenic BRAF to Drive Primary Cutaneous Melanomas and Angiotropic Lung Metastases in Mice. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1410-1417.e2.	0.7	3
15	Pancreatic panniculitis with polyarthritis (PPP syndrome). <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 546-547.	0.8	2
16	Direct targeting of G1q and G11 oncoproteins in cancer cells. <i>Science Signaling</i> , 2019, 12, .	3.6	84
17	Age as key factor for pattern, timing, and extent of distant metastasis in patients with cutaneous melanoma: A study of the German Central Malignant Melanoma Registry. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1299-1307.e7.	1.2	8
18	Live or Let Die: T Cell Survival in Cancer Immunotherapy. <i>Immunity</i> , 2019, 50, 280-282.	14.3	2

#	ARTICLE	IF	CITATIONS
19	Pankreatische Pannikulitis mit Polyarthrit (PPP-Syndrom). JDDG - Journal of the German Society of Dermatology, 2019, 17, 546-548.	0.8	7
20	Role of the Aryl Hydrocarbon Receptor in Environmentally Induced Skin Aging and Skin Carcinogenesis. International Journal of Molecular Sciences, 2019, 20, 6005.	4.1	55
21	Tissue-resident memory CD8+ T cells promote melanoma-immune equilibrium in skin. Nature, 2019, 565, 366-371.	27.8	266
22	Detection of a multilineage mosaic NRAS mutation c.181C>A (p.Gln61Lys) in an individual with a complex congenital nevus syndrome. Pigment Cell and Melanoma Research, 2019, 32, 470-473.	3.3	3
23	Safety and Efficacy of Topically Applied Selected Cutibacterium acnes Strains over Five Weeks in Patients with Acne Vulgaris: An Open-label, Pilot Study. Acta Dermato-Venereologica, 2019, 99, 1253-1257.	1.3	24
24	Systematic assessment of LCMV based vaccine vectors expressing melanocyte differentiation antigens in human in vitro assays and in mouse melanoma models.. Journal of Clinical Oncology, 2019, 37, e14299-e14299.	1.6	0
25	Acral lentiginous melanoma: a skin cancer with unfavourable prognostic features. A study of the German central malignant melanoma registry (CMMR) in 2050 patients. British Journal of Dermatology, 2018, 178, 443-451.	1.5	78
26	Widespread spontaneous hyperproliferation, melanosis and melanoma in Hgf-Cdk4 R24C mice. Melanoma Research, 2018, 28, 76-78.	1.2	2
27	RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. Oncogene, 2018, 37, 6136-6151.	5.9	91
28	Restoration of Endogenous Retrovirus Infectivity Impacts Mouse Cancer Models. Cancer Immunology Research, 2018, 6, 1292-1300.	3.4	21
29	Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma. Genes and Development, 2017, 31, 18-33.	5.9	184
30	The epidermal polarity protein Par3 is a non-cell autonomous suppressor of malignant melanoma. Journal of Experimental Medicine, 2017, 214, 339-358.	8.5	37
31	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology, 2017, 6, e1320626.	4.6	89
32	RIG-I Resists Hypoxia-Induced Immunosuppression and Dedifferentiation. Cancer Immunology Research, 2017, 5, 455-467.	3.4	29
33	Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis. Oncogene, 2017, 36, 5058-5067.	5.9	13
34	Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. Nature, 2017, 541, 233-236.	27.8	194
35	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity, 2017, 47, 789-802.e9.	14.3	207
36	MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Research, 2017, 77, 4697-4709.	0.9	126

#	ARTICLE	IF	CITATIONS
37	Basophils Promote Tumor Rejection via Chemotaxis and Infiltration of CD8+ T Cells. <i>Cancer Research</i> , 2017, 77, 291-302.	0.9	68
38	Regulatory Role of Cannabinoids for Skin Barrier Functions and Cutaneous Inflammation. , 2017, , 543-549.		1
39	Melanoma Model Systems. , 2017, , 369-398.		1
40	Abstract 5596: Intratumoral administration of a TLR9-adjuvanted nanoparticle cancer vaccine stimulates more effective immunity in both injected and un-injected tumor sites compared to subcutaneous administration. , 2017, , .		0
41	Directed Dedifferentiation Using Partial Reprogramming Induces Invasive Phenotype in Melanoma Cells. <i>Stem Cells</i> , 2016, 34, 832-846.	3.2	27
42	Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma. <i>Melanoma Research</i> , 2016, 26, 89-91.	1.2	2
43	A stochastic model for immunotherapy of cancer. <i>Scientific Reports</i> , 2016, 6, 24169.	3.3	42
44	Structural decoding of netrin-4 reveals a regulatory function towards mature basement membranes. <i>Nature Communications</i> , 2016, 7, 13515.	12.8	74
45	How neutrophils promote metastasis. <i>Science</i> , 2016, 352, 145-146.	12.6	81
46	Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis. <i>Trends in Immunology</i> , 2016, 37, 364-374.	6.8	59
47	RIG-I activation induces the release of extracellular vesicles with antitumor activity. <i>OncImmunology</i> , 2016, 5, e1219827.	4.6	44
48	Die tumorimmunologische Revolution in der Behandlung des fortgeschrittenen Melanoms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 655-656.	0.8	0
49	Inflammasome-Dependent Induction of Adaptive NK Cell Memory. <i>Immunity</i> , 2016, 44, 1406-1421.	14.3	67
50	The Role of Neutrophilic Inflammation, Angiotropism, and Pericytic Mimicry in Melanoma Progression and Metastasis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 372-377.	0.7	25
51	Phorbol ester-induced neutrophilic inflammatory responses selectively promote metastatic spread of melanoma in a TLR4-dependent manner. <i>OncImmunology</i> , 2016, 5, e1078964.	4.6	13
52	A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells. <i>Cancer Research</i> , 2016, 76, 251-263.	0.9	33
53	Genome-wide association study identifies new susceptibility loci for cutaneous lupus erythematosus. <i>Experimental Dermatology</i> , 2015, 24, 510-515.	2.9	66
54	Dickkopf-3 Contributes to the Regulation of Anti-Tumor Immune Responses by Mesenchymal Stem Cells. <i>Frontiers in Immunology</i> , 2015, 6, 645.	4.8	15

#	ARTICLE	IF	CITATIONS
55	The experimental power of FR900359 to study Gq-regulated biological processes. <i>Nature Communications</i> , 2015, 6, 10156.	12.8	282
56	Differential role of cannabinoids in the pathogenesis of skin cancer. <i>Life Sciences</i> , 2015, 138, 35-40.	4.3	49
57	Self-Antigen Presentation by Keratinocytes in the Inflamed Adult Skin Modulates T-Cell Auto-Reactivity. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1996-2004.	0.7	16
58	MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. <i>Nature Communications</i> , 2015, 6, 8755.	12.8	175
59	“Glowing Head” Mice: A Genetic Tool Enabling Reliable Preclinical Image-Based Evaluation of Cancers in Immunocompetent Allografts. <i>PLoS ONE</i> , 2014, 9, e109956.	2.5	28
60	Cannabinoid 1 receptors in keratinocytes attenuate fluorescein isothiocyanate-induced mouse atopic-like dermatitis. <i>Experimental Dermatology</i> , 2014, 23, 401-406.	2.9	27
61	Immune Cell “Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. <i>Cancer Discovery</i> , 2014, 4, 674-687.	9.4	226
62	Ultraviolet-radiation-induced inflammation promotes angiogenesis and metastasis in melanoma. <i>Nature</i> , 2014, 507, 109-113.	27.8	547
63	Î2-Arrestin 2 Inhibits Proinflammatory Chemokine Production and Attenuates Contact Allergic Inflammation in the Skin. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2131-2137.	0.7	12
64	Cancer cell “autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309.	30.7	823
65	A Cell-Permeable Inhibitor to Trap GÎ±q Proteins in the Empty Pocket Conformation. <i>Chemistry and Biology</i> , 2014, 21, 890-902.	6.0	47
66	Melanoma Vaccines. , 2014, , 2713-2717.		0
67	Biostic DNA Vaccination Against Melanoma. <i>Methods in Molecular Biology</i> , 2013, 940, 317-337.	0.9	5
68	Oxidative Damage of DNA Confers Resistance to Cytosolic Nuclease TREX1 Degradation and Potentiates STING-Dependent Immune Sensing. <i>Immunity</i> , 2013, 39, 482-495.	14.3	338
69	Nitrosative stress: a hallmark of the junctional inflammation in cutaneous lupus erythematosus. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 96-97.	1.3	13
70	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. <i>Nature Reviews Cancer</i> , 2013, 13, 365-376.	28.4	242
71	T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 441-456.	3.3	11
72	Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 994-1000.	5.7	58

#	ARTICLE	IF	CITATIONS
73	Cannabinoid 1 Receptors in Keratinocytes Modulate Proinflammatory Chemokine Secretion and Attenuate Contact Allergic Inflammation. <i>Journal of Immunology</i> , 2013, 190, 4929-4936.	0.8	41
74	Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. <i>Nature</i> , 2012, 490, 412-416.	27.8	506
75	Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. <i>Clinical and Experimental Dermatology</i> , 2012, 37, 139-142.	1.3	34
76	Excitation-induced ataxin-3 aggregation in neurons from patients with Machadoâ€“Joseph disease. <i>Nature</i> , 2011, 480, 543-546.	27.8	282
77	Enhanced CCR5+/CCR3+ T helper cell ratio in patients with active cutaneous lupus erythematosus. <i>Lupus</i> , 2011, 20, 1300-1304.	1.6	34
78	PS1-030. Tyrosine kinase inhibitor SU6668 blocks the polyIC-induced IFNÎ»-expression of keratinocytes: TBK1 as a potential drug-target for the treatment of cutaneous lupus erythematosus. <i>Cytokine</i> , 2011, 56, 24.	3.2	0
79	Enhanced skin expression of melanoma differentiation-associated gene 5 (MDA5) in dermatomyositis and related autoimmune diseases. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 988-989.	1.2	28
80	Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. <i>Vaccine</i> , 2011, 29, 2313-2321.	3.8	18
81	Interferon-Î± stimulates TRAIL expression in human keratinocytes and peripheral blood mononuclear cells: implications for the pathogenesis of cutaneous lupus erythematosus. <i>British Journal of Dermatology</i> , 2011, 165, 1118-1123.	1.5	36
82	Evidence for a Pathophysiological Role of Keratinocyte-Derived Type III Interferon (IFNÎ») in Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , 2011, 131, 133-140.	0.7	110
83	Immunogenic cell death of human ovarian cancer cells induced by cytosolic poly(I:C) leads to myeloid cell maturation and activates NK cells. <i>European Journal of Immunology</i> , 2011, 41, 3028-3039.	2.9	40
84	Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in Hgfâ€“Cdk4^{R24C} C57BL/6 mice. <i>International Journal of Cancer</i> , 2011, 129, 285-294.	5.1	32
85	Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine. <i>Cancer Research</i> , 2011, 71, 5827-5837.	0.9	31
86	Melanoma Model Systems. , 2011, , 309-335.		0
87	Melanoma Vaccines. , 2011, , 2212-2215.		0
88	Protective role of palmitoylethanolamide in contact allergic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 698-711.	5.7	104
89	Identification of a 17Î²-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 113-24.	4.2	9
90	Bioluminescence imaging allows measuring CD8 T cell function in the liver. <i>Hepatology</i> , 2010, 51, 1430-1437.	7.3	38

#	ARTICLE	IF	CITATIONS
91	Effective collaboration between marginal metallophilic macrophages and CD8 ⁺ dendritic cells in the generation of cytotoxic T cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 216-221.	7.1	160
92	Multicentre study on standardisation of melanoma cell culture - an initiative of the German Melanoma Research Network. Pigment Cell and Melanoma Research, 2010, 23, 296-298.	3.3	4
93	Autochthonous primary and metastatic melanomas in Hgfâ€Cdk4 ^{R24C} mice evade Tâ€cellâ€mediated immune surveillance. Pigment Cell and Melanoma Research, 2010, 23, 649-660.	3.3	34
94	Of swords and ploughshares: immunosurveillance and inflammation in melanoma. Pigment Cell and Melanoma Research, 2010, 23, 727-728.	3.3	1
95	Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets. Lupus, 2010, 19, 1020-1028.	1.6	45
96	Screening of Human Tumor Antigens for CD4+ T Cell Epitopes by Combination of HLA-Transgenic Mice, Recombinant Adenovirus and Antigen Peptide Libraries. PLoS ONE, 2010, 5, e14137.	2.5	15
97	Complete Regression of Advanced Primary and Metastatic Mouse Melanomas following Combination Chemoimmunotherapy. Cancer Research, 2009, 69, 6265-6274.	0.9	46
98	Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells. Cancer Cell, 2009, 16, 103-114.	16.8	163
99	Autochthonous liver tumors induce systemic T cell tolerance associated with T cell receptor down-modulation. Hepatology, 2009, 49, 471-481.	7.3	13
100	Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Archives of Dermatological Research, 2009, 301, 83-86.	1.9	62
101	Interferon-Î± Differentially Affects Homeostasis of Human Plasmacytoid and Myeloid Dendritic Cells. Journal of Interferon and Cytokine Research, 2009, 29, 145-160.	1.2	6
102	Transcriptional profiling identifies an interferonâ€associated host immune response in invasive squamous cell carcinoma of the skin. International Journal of Cancer, 2008, 123, 2605-2615.	5.1	27
103	An IFN-Associated Cytotoxic Cellular Immune Response against Viral, Self-, or Tumor Antigens Is a Common Pathogenetic Feature in â€œInterface Dermatitisâ€. Journal of Investigative Dermatology, 2008, 128, 2392-2402.	0.7	151
104	5â€triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nature Medicine, 2008, 14, 1256-1263.	30.7	353
105	Gene Expression Profiling of Lichen Planus Reflects CXCL9+-Mediated Inflammation and Distinguishes this Disease from Atopic Dermatitis and Psoriasis. Journal of Investigative Dermatology, 2008, 128, 67-78.	0.7	68
106	SÃ©zary syndrome is a unique cutaneous T-cell lymphoma as identified by an expanded gene signature including diagnostic marker molecules CDO1 and DNM3. Leukemia, 2008, 22, 393-399.	7.2	94
107	Subacute cutaneous lupus erythematosus in a leuprorelin-treated patient with prostate carcinoma. British Journal of Dermatology, 2008, 159, 231-233.	1.5	18
108	Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab. Clinical and Experimental Dermatology, 2008, 33, 347-348.	1.3	12

#	ARTICLE	IF	CITATIONS
109	CXCR3 <-> ligandâ€‘mediated skin inflammation in cutaneous lichenoid graft-versus-host disease. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 437-442.	1.2	36
110	Toll-Like Receptor-Agonists in the Treatment of Skin Cancer: History, Current Developments and Future Prospects. <i>Handbook of Experimental Pharmacology</i> , 2008, , 201-220.	1.8	12
111	Preoperative 18F-FDG-PET/CT imaging and sentinel node biopsy in the detection of regional lymph node metastases in malignant melanoma. <i>Melanoma Research</i> , 2008, 18, 346-352.	1.2	58
112	Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System. <i>Science</i> , 2007, 316, 1494-1497.	12.6	302
113	IP10/CXCL10 - CXCR3 Interaction: a Potential Self-recruiting Mechanism for Cytotoxic Lymphocytes in Lichen Sclerosus et Atrophicus. <i>Acta Dermato-Venereologica</i> , 2007, 87, 112-117.	1.3	41
114	Successful Treatment of Bullous Congenital Ichthyosiform Erythroderma with Erythromycin. <i>Dermatology</i> , 2007, 215, 81-83.	2.1	1
115	CXCR3-mediated recruitment of cytotoxic lymphocytes in lupus erythematosus profundus. <i>Journal of the American Academy of Dermatology</i> , 2007, 56, 648-650.	1.2	40
116	Indoleamine 2,3-Dioxygenase (IDO). <i>American Journal of Pathology</i> , 2007, 171, 1936-1943.	3.8	52
117	Loss-of-Function Mutations in the Filaggrin Gene and Alopecia Areata: Strong Risk Factor for a Severe Course of Disease in Patients Comorbid for Atopic Disease. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2539-2543.	0.7	87
118	The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. <i>British Journal of Dermatology</i> , 2007, 157, 752-757.	1.5	120
119	The R620W polymorphism in PTPN22 confers general susceptibility for the development of alopecia areata. <i>British Journal of Dermatology</i> , 2007, 158, 071119222739011-???	1.5	45
120	Identification of type I interferon-associated inflammation in the pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic approaches. <i>Experimental Dermatology</i> , 2007, 16, 454-463.	2.9	73
121	Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells. <i>European Journal of Cell Biology</i> , 2007, 86, 817-826.	3.6	15
122	Rapid Growth of Invasive Metastatic Melanoma in Carcinogen-Treated Hepatocyte Growth Factor/Scatter Factor-Transgenic Mice Carrying an Oncogenic CDK4 Mutation. <i>American Journal of Pathology</i> , 2006, 169, 665-672.	3.8	53
123	Type I interferonâ€‘associated cytotoxic inflammation in lichen planus. <i>Journal of Cutaneous Pathology</i> , 2006, 33, 672-678.	1.3	107
124	Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. <i>Clinical and Experimental Dermatology</i> , 2006, 31, 576-582.	1.3	113
125	Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination. <i>Cancer Gene Therapy</i> , 2006, 13, 318-325.	4.6	22
126	Additional Her 2/neu gene copies in patients with SÄ‘zary syndrome. <i>Leukemia Research</i> , 2006, 30, 755-760.	0.8	12

#	ARTICLE	IF	CITATIONS
127	Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration. <i>British Journal of Dermatology</i> , 2006, 155, 861-862.	1.5	26
128	Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 246-253.	4.2	62
129	Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes. <i>Journal of Immunological Methods</i> , 2006, 308, 77-89.	1.4	10
130	Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. <i>European Journal of Immunology</i> , 2006, 36, 12-20.	2.9	153
131	Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against autochthonous melanomas in the skin. <i>International Journal of Cancer</i> , 2006, 118, 373-380.	5.1	12
132	Evaluation of DNA vaccination with recombinant adenoviruses using bioluminescence imaging of antigen expression: impact of application routes and delivery with dendritic cells. <i>Journal of Gene Medicine</i> , 2006, 8, 1243-1250.	2.8	22
133	Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN- γ production. <i>Journal of Gene Medicine</i> , 2006, 8, 1300-1306.	2.8	99
134	Treatment of Recalcitrant Dermatomyositis with Efalizumab. <i>Acta Dermato-Venereologica</i> , 2006, 86, 254-255.	1.3	24
135	Therapeutic Efficacy of Antigen-Specific Vaccination and Toll-Like Receptor Stimulation against Established Transplanted and Autochthonous Melanoma in Mice. <i>Cancer Research</i> , 2006, 66, 5427-5435.	0.9	59
136	Diagnostic Performance of Whole Body Dual Modality ^{18}F -FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 1178-1187.	1.6	257
137	Circulating clonal CLA+ and CD4+ T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. <i>British Journal of Dermatology</i> , 2005, 152, 258-264.	1.5	105
138	Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. <i>British Journal of Dermatology</i> , 2005, 153, 157-162.	1.5	123
139	Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. <i>British Journal of Dermatology</i> , 2005, 153, 1011-1015.	1.5	114
140	Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. <i>British Journal of Dermatology</i> , 2005, 153, 462-463.	1.5	33
141	Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sezary syndrome. <i>Clinical and Experimental Dermatology</i> , 2005, 30, 702-706.	1.3	54
142	Peripheral CD8+ T Cell Tolerance Against Melanocytic Self-Antigens in the Skin Is Regulated in Two Steps by CD4+ T Cells and Local Inflammation: Implications for the Pathophysiology of Vitiligo. <i>Journal of Investigative Dermatology</i> , 2005, 124, 144-150.	0.7	45
143	Role of the Chemokine Receptor CCR4 and its Ligand Thymus- and Activation-Regulated Chemokine/CCL17 for Lymphocyte Recruitment in Cutaneous Lupus Erythematosus. <i>Journal of Investigative Dermatology</i> , 2005, 124, 1241-1248.	0.7	63
144	The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. <i>Experimental Dermatology</i> , 2005, 14, 454-459.	2.9	39

#	ARTICLE	IF	CITATIONS
145	Impact of p53-based immunization on primary chemically-induced tumors. <i>International Journal of Cancer</i> , 2005, 113, 961-970.	5.1	11
146	Altered intracellular sorting signals do not influence the efficacy of genetic melanoma vaccines incorporating helper determinants in mice. <i>Journal of Gene Medicine</i> , 2005, 7, 613-620.	2.8	0
147	Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. <i>Journal of Pathology</i> , 2005, 205, 435-442.	4.5	202
148	Successful Rituximab Treatment of Severe Pemphigus Vulgaris Resistant to Multiple Immunosuppressants. <i>Acta Dermato-Venereologica</i> , 2005, -1, 1-1.	1.3	12
149	Type I Interferon-Associated Recruitment of Cytotoxic Lymphocytes. <i>American Journal of Clinical Pathology</i> , 2005, 124, 37-48.	0.7	88
150	The role of cytotoxic skin-homing CD8+ lymphocytes in cutaneous cytotoxic T-cell lymphoma and pityriasis lichenoides. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 422-427.	1.2	33
151	Type I Interferon-Associated Recruitment of Cytotoxic Lymphocytes. <i>American Journal of Clinical Pathology</i> , 2005, 124, 37-48.	0.7	3
152	Therapeutic Effectiveness of Recombinant Cancer Vaccines Is Associated with a Prevalent T-Cell Receptor β Usage by Melanoma-specific CD8+ T Lymphocytes. <i>Cancer Research</i> , 2004, 64, 8068-8076.	0.9	22
153	Early Adenoviral Gene Expression Mediates Immunosuppression by Transduced Dendritic Cell (DC): Implications for Immunotherapy Using Genetically Modified DC. <i>Journal of Immunology</i> , 2004, 172, 1524-1530.	0.8	17
154	Successful treatment of recalcitrant Wegener's granulomatosis of the skin with tacrolimus (Prograf TM). <i>British Journal of Dermatology</i> , 2004, 151, 927-928.	1.5	15
155	Initiation and regulation of CD8+T cells recognizing melanocytic antigens in the epidermis: Implications for the pathophysiology of vitiligo. <i>European Journal of Cell Biology</i> , 2004, 83, 797-803.	3.6	48
156	Priming of T cells with aAd-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy. <i>Gene Therapy</i> , 2003, 10, 243-250.	4.5	40
157	Transcriptional targeting of dendritic cells for gene therapy using the promoter of the cytoskeletal protein fascin. <i>Gene Therapy</i> , 2003, 10, 1035-1040.	4.5	55
158	Efficacy of recombinant adenovirus as vector for allergen gene therapy in a mouse model of type I allergy. <i>Gene Therapy</i> , 2002, 9, 147-156.	4.5	21
159	Genetic immunization with a melanocytic self-antigen linked to foreign helper sequences breaks tolerance and induces autoimmunity and tumor immunity. <i>Gene Therapy</i> , 2002, 9, 208-213.	4.5	44
160	Interleukin-10-Treated Dendritic Cells Modulate Immune Responses of Naive and Sensitized T Cells In Vivo. <i>Journal of Investigative Dermatology</i> , 2002, 119, 836-841.	0.7	71
161	A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. <i>International Journal of Cancer</i> , 2001, 93, 243-251.	5.1	353
162	Adenovirus-transduced dendritic cells stimulate cellular immunity to melanoma via a CD4+ T cell-dependent mechanism. <i>Gene Therapy</i> , 2001, 8, 1255-1263.	4.5	80

#	ARTICLE	IF	CITATIONS
163	The Immunology of DNA Vaccines. , 2000, 29, 37-64.		4
164	Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma. International Journal of Cancer, 2000, 86, 89-94.	5.1	95
165	Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T cell stimulatory capacity. Gene Therapy, 2000, 7, 249-254.	4.5	61
166	Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. Gene Therapy, 2000, 7, 2036-2040.	4.5	159
167	Induction of dendritic cell maturation and modulation of dendritic cell-induced immune responses by prostaglandins. Archives of Dermatological Research, 2000, 292, 437-445.	1.9	64
168	Particle-Mediated Gene Transfer into Dendritic Cells: A Novel Strategy for the Induction of Immune Responses against Tumor Antigens. , 2000, 35, 27-47.		1
169	IFN-Î±-Expressing Tumor Cells Enhance Generation and Promote Survival of Tumor-Specific CTLs. Journal of Immunology, 2000, 164, 567-572.	0.8	79
170	Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Therapy, 1999, 6, 45-53.	4.6	72
171	Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. Cancer Gene Therapy, 1999, 6, 73-80.	4.6	69
172	Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen Î²-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Therapy, 1999, 6, 629-636.	4.5	45
173	Interferon-alpha gene therapy in combination with CD80 transduction reduces tumorigenicity and growth of established tumor in poorly immunogenic tumor models. Gene Therapy, 1999, 6, 1988-1994.	4.5	26
174	Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. Journal of Gene Medicine, 1999, 1, 400-406.	2.8	65
175	DNA Immunization Targeting the Skin: Molecular Control of Adaptive Immunity. Journal of Investigative Dermatology, 1998, 111, 183-188.	0.7	91
176	Adjuvant administration of plasmid DNA expressing IL-12 enhances the induction of anti-melanoma immune responses with plasmid DNA encoding the murine melanosomal protein TRP-2. Journal of Dermatological Science, 1998, 16, S14.	1.9	0
177	DNA Vaccines Targeting Dendritic Cells for the Immunotherapy of Cancer. Advances in Experimental Medicine and Biology, 1998, 451, 295-304.	1.6	5
178	Dendritic cell-based therapy for cancer. European Journal of Cancer, 1997, 33, S21.	2.8	0
179	Interferon-Î± gene therapy for cancer: retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are both effective strategies for gene delivery in murine tumor models. Gene Therapy, 1997, 4, 1053-1060.	4.5	42
180	Gene-based strategies for the immunotherapy of cancer. Journal of Molecular Medicine, 1997, 75, 478-491.	3.9	67

#	ARTICLE	IF	CITATIONS
181	Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or self-antigens induce antitumor immunity in vivo. <i>European Journal of Immunology</i> , 1997, 27, 2702-2707.	2.9	119
182	Development of Dendritic Cell-Based Genetic Vaccines for Cancer. <i>Advances in Experimental Medicine and Biology</i> , 1997, 417, 511-518.	1.6	4
183	Primary plasmacytoma of the skin. <i>Journal of the American Academy of Dermatology</i> , 1996, 34, 386-390.	1.2	61
184	Melanoma Vaccines. , 0, , 1812-1815.		0